Australian Government

BE COVIDSAFE

Criteria for access to remdesivir from the National Medical Stockpile.

Treatment course is limited to 5 days for eligible patients. Applications must be signed by treating consultant clinician (FRACP, FCICM or equivalent).

Inclusion Criteria:

- Informed consent provided by the patient,or patient's legal representative.
- Age ≥ 18 years, or aged ≥ 12 and < 18 years of age weighing ≥ 40 kg.
- Hospitalised with confirmed SARS-CoV2 or known contact of confirmed case with syndrome consistent with coronavirus disease (COVID-19) awaiting confirmation by diagnostic testing.
- Oxygen saturation (SpO2) ≤ 92% on room air and requiring supplemental oxygen
- Alanine aminotransferase (ALT) < 5 x upper limit of normal (ULN) by local laboratory measure and/or ALT < 3 x ULN and bilirubin < 2 x ULN

Exclusion Criteria:

- Evidence of multiorgan failure including but not limited to coagulopathy (significant thrombocytopenia), hepatic failure (elevated bilirubin) or renal failure (low urine output or estimated glomerular filtration rate (eGFR) < 30 mL/min), or significant cardiomyopathy (low cardiac output)
- Renal failure (eGFR < 30 mL/min or dialysis or continuous venovenous haemofiltration
- Mechanical ventilation for longer than 48 hours at time of application
- Receiving ECMO
- Known hypersensitivity to the study drug, the metabolites, or formulation excipient

Special Considerations

The clinical benefit of remdesivir is uncertain in the following scenarios. Clinicians should give strong consideration to whether remdesivir is likely to benefit the patient in the following scenarios:

- Mechanical ventilation for less than 48 hours at time of application.
- Presence of an intercurrent illness which is likely to lead to the patient's death within one year
- Advanced age with limitations on activities of daily living.
- Need for more than a 5 day treatment course

For applications where these considerations apply the Department may contact the prescribing clinician for further information.

PLEASE NOTE - REMDESIVIR IS SUPPLIED IN THIS PROGRAM FOR CLINICAL USE ONLY – IT IS NOT FOR USE IN CLINICAL TRIALS